EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Triple combination cystic fibrosis transmembrane receptor modulator effects on glycaemia and insulin kinetics in cystic fibrosis with and without diabetes

Yi W Chen iD, Rachel Prasad, Peter G Middleton, D Jane Holmes-Walker iD

Internal Medicine Journal · 2026-08 · 56 (8) · 1356-1360

DOI: 10.1111/imj.70471 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Internal Medicine Journal, online erschienen am 24.06.2026. Verfasst von Yi W Chen und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Nepean Hospital, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Cystic Fibrosis, Blood Glucose, Insulin, Quinolones. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Greater insight into the effects of cystic fibrosis (CF) transmembrane modulators such as elexacaftor‐tezacaftor‐ivacaftor (ETI) on glucose metabolism can support a more dynamic and individualised approach to CF‐related dysglycaemia.

Aim

To assess changes in glycemia, body weight and pulmonary function in adults with CF with and without cystic fibrosis related diabetes (CFRD) following ETI.

Methods

This single‐centre retrospective cohort study included adults with at least one F508del mutation (23 with CFRD, 38 without CFRD). Exploratory outcomes were HbA1c and total daily insulin doses in the CFRD group and glucose and insulin profiles (0–120 min oral glucose tolerance test [OGTT]), HOMA2‐derived indices of insulin resistance (IR), secretion (%S), and β‐cell function (%B) in the non‐CFRD group. Pulmonary function and weight were assessed in both groups.

Results

Mean age was 33.8 ± 10.0 years (CFRD) and 32.8 ± 8.8 years (non‐CFRD), with median ETI exposure of 12.3 and 13.4 months, respectively. In the CFRD cohort, HbA1c decreased non‐significantly (6.6% to 6.1%, p = 0.2) with no significant change in insulin dose (0.28 to 0.20 IU/kg/day, p = 0.1). In non‐CFRD participants, ETI significantly reduced 1‐ and 2‐hour OGTT glucose levels (9.6 vs. 9.2 mmol/L at 1 h, p < 0.01; 6.1 vs. 4.8 mmol/L at 2 hours, p = 0.01), with 13/38 participants improving OGTT classification; no progression to CFRD occurred. Lung function improved in both groups.

Conclusions

Adults with at least one F508del mutation, ETI was associated with a clinically relevant reduction in HbA1c in those with CFRD and improved glucose tolerance in those without, supporting favourable metabolic effects beyond established respiratory benefits.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisBlood GlucoseInsulinQuinolonesAminophenolsIndolesDiabetes MellitusPyrrolidinesBenzodioxolesCystic Fibrosis Transmembrane Conductance RegulatorHumansFemaleAdultMaleRetrospective StudiesPyrazolesPyridinesGlycated HemoglobinCohort StudiesGlucose Tolerance Test

Stichwörter der Autor:innen

Cystic fibrosis‐related diabeteselexacaftor‐tezacaftor‐ivacaftorglucose metabolisminsulin kinetics

Substanzen

Blood GlucoseInsulinQuinolonesAminophenolsIndolesPyrrolidinesBenzodioxolesPyrazolesPyridinesCystic Fibrosis Transmembrane Conductance Regulator

Autor:innen und Institutionen

  • Department of Endocrinology, Nepean Hospital, Sydney, New South Wales, Australia.
  • Department of Respiratory and Sleep Medicine, Westmead Hospital, Sydney, New South Wales, Australia.
  • Department of Diabetes and Endocrinology, Westmead Hospital, Sydney, New South Wales, Australia.

ORCID-Profile: Yi W Chen, D Jane Holmes-Walker

Zitieren

APA

Chen, Y. W., Prasad, R., Middleton, P. G., & Holmes-Walker, D. J. (2026). Triple combination cystic fibrosis transmembrane receptor modulator effects on glycaemia and insulin kinetics in cystic fibrosis with and without diabetes. Internal Medicine Journal, 56(8), 1356-1360. https://doi.org/10.1111/imj.70471

Vancouver

Chen YW, Prasad R, Middleton PG, Holmes-Walker DJ. Triple combination cystic fibrosis transmembrane receptor modulator effects on glycaemia and insulin kinetics in cystic fibrosis with and without diabetes. Internal Medicine Journal. 2026;56(8):1356-1360. doi:10.1111/imj.70471

BibTeX
@article{Chen2026,
  author = {Chen, Yi W and Prasad, Rachel and Middleton, Peter G and Holmes-Walker, D Jane},
  title = {Triple combination cystic fibrosis transmembrane receptor modulator effects on glycaemia and insulin kinetics in cystic fibrosis with and without diabetes},
  journal = {Internal Medicine Journal},
  year = {2026},
  volume = {56},
  number = {8},
  pages = {1356--1360},
  doi = {10.1111/imj.70471}
}
Kostenlos starten →